Progress of targeting PI3K-AKT-mTOR signaling pathway inhibitors in treatment of triple-negative breast cancer
10.3760/cma.j.cn115355-20190917-00422
- VernacularTitle:PI3K-AKT-mTOR信号通路抑制剂靶向治疗三阴性乳腺癌的研究进展
- Author:
Peiyu LI
1
;
Fuguo TIAN
Author Information
1. 山西医科大学研究生院，太原 030001
- From:
Cancer Research and Clinic
2020;32(8):525-528
- CountryChina
- Language:Chinese
-
Abstract:
Triple-negative breast cancer (TNBC) is a subtype of breast cancer, which has the biological characteristics of high invasiveness, early recurrence, rapid progression and easy invasion. Current studies have demonstrated that abnormal activation of the PI3K-AKT-mTOR signaling pathway is more common in TNBC. This article reviews the abnormal activation mechanism of PI3K-AKT-mTOR signaling pathway, related clinical progress and the application of related targeted inhibitors to provide more approaches for investigational therapies in TNBC.
